Phoenix WNL to handle 2x2 crossover study with multip group [Software]

posted by zan – US, 2014-06-28 01:29 (3951 d 04:37 ago) – Posting: # 13161
Views: 29,328

Hi All,
I am working on a 2x2 crossover BE study with large N (N=54). Due to limited clinical capacity the site separated subjects into two dosing groups (N=27 each). I have come across several discussion threads in the forum regarding the use of SAS model to deal with this issue, however, I would like to see how is this modeled correctly in Phoenix Winnonlin 6.3 as I only have WNL available.
Per FDA guidance the model should reflect that the periods in the first group are different from the periods in the second group. I immediately have two thoughts about this:
  1. is it acceptable to just assign 4 periods to the 4 dosing days? If so,
    In the model specification: Treatment+Sequence+Period
    and in the variance structure--Random effect: Subject(Sequence).
    Is there any issue with this approach? It looks to me these periods are independent occasions, which might not really separate each two periods for the same group.
  2. Can we still keep these 2 periods and add a Group term to these subjects (eg. Group 1 and Group 2)?. If so, in the model specification:
    Treatment+Sequence+Period+Group
    but in the variance structure, I dont know what is appropriate to be added in the Random effect field. Should it be Subject(Sequence*Group).
I wanted to make sure I choose the correct procedure in PHX Winnonlin so that when FDA asks whether we properly deal with the issue with multiple dosing groups.

Really appreciate for any help.

Zan


Edit: Category changed. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
25 visitors (0 registered, 25 guests [including 6 identified bots]).
Forum time: 06:07 CEST (Europe/Vienna)

The true Enlightenment thinker, the true rationalist,
never wants to talk anyone into anything.
No, he does not even want to convince;
all the time he is aware that he may be wrong.    Karl R. Popper

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5